|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0003250,
umls-concept:C0034819,
umls-concept:C0080103,
umls-concept:C0085358,
umls-concept:C0087111,
umls-concept:C0332282,
umls-concept:C0441889,
umls-concept:C0597357,
umls-concept:C0856825,
umls-concept:C0871261,
umls-concept:C1332717,
umls-concept:C1413244,
umls-concept:C1456820,
umls-concept:C1704632,
umls-concept:C1706438,
umls-concept:C1706817,
umls-concept:C1749467,
umls-concept:C2698600,
umls-concept:C2911692
|
|
pubmed:issue |
3
|
|
pubmed:dateCreated |
1991-10-18
|
|
pubmed:abstractText |
Serial determination of soluble CD8 (sCD8), soluble IL-2 receptors (sIL-2R), and tumor necrosis factor-alpha serum levels were performed in bone marrow transplant patients upon initiation, day 0 (D0) and at D10 of an anti-IL-2 receptor (alpha chain) monoclonal antibody (B-B10) in vivo treatment for steroid-resistant grade greater than or equal to 2 acute graft-versus-host disease (aGVHD). D0 and D10 sCD8 serum levels correlated strongly with response to B-B10 treatment (p = .003 and .001, respectively); 76% of the patients with D0 sCD8 levels less than 500 U/ml responded favorably to B-B10 treatment, versus only a 30% response if the sCD8 levels were greater than 500 U/ml (p = .02). Likewise, D0 tumor necrosis factor-alpha levels significantly correlated with subsequent response to B-B10 treatment (p = .03). D0 sIL-2R levels were not significantly different in B-B10-responsive and nonresponsive aGVHD patients. These results suggest that the serial determination of sCD8 and TNF serum levels could provide valuable predictive information as to steroid-resistant aGVHD responsiveness to anti-IL-2R treatment.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Adrenal Cortex Hormones,
http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Monoclonal,
http://linkedlifedata.com/resource/pubmed/chemical/Antigens, CD,
http://linkedlifedata.com/resource/pubmed/chemical/Antigens, CD8,
http://linkedlifedata.com/resource/pubmed/chemical/Antigens, Differentiation...,
http://linkedlifedata.com/resource/pubmed/chemical/Receptors, Interleukin-2,
http://linkedlifedata.com/resource/pubmed/chemical/Tumor Necrosis Factor-alpha
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Sep
|
|
pubmed:issn |
0041-1337
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
52
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
475-80
|
|
pubmed:dateRevised |
2004-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:1910217-Adolescent,
pubmed-meshheading:1910217-Adrenal Cortex Hormones,
pubmed-meshheading:1910217-Adult,
pubmed-meshheading:1910217-Antibodies, Monoclonal,
pubmed-meshheading:1910217-Antigens, CD,
pubmed-meshheading:1910217-Antigens, CD8,
pubmed-meshheading:1910217-Antigens, Differentiation, T-Lymphocyte,
pubmed-meshheading:1910217-Bone Marrow Transplantation,
pubmed-meshheading:1910217-Child,
pubmed-meshheading:1910217-Child, Preschool,
pubmed-meshheading:1910217-Drug Resistance,
pubmed-meshheading:1910217-Female,
pubmed-meshheading:1910217-Graft vs Host Disease,
pubmed-meshheading:1910217-Humans,
pubmed-meshheading:1910217-Male,
pubmed-meshheading:1910217-Receptors, Interleukin-2,
pubmed-meshheading:1910217-Tumor Necrosis Factor-alpha
|
|
pubmed:year |
1991
|
|
pubmed:articleTitle |
Soluble CD8, IL-2 receptor, and tumor necrosis factor-alpha levels in steroid-resistant acute graft-versus-host disease. Relation with subsequent response to anti-IL-2 receptor monoclonal antibody treatment.
|
|
pubmed:affiliation |
Service d'Hematologie, CHU Besancon, France.
|
|
pubmed:publicationType |
Journal Article
|
